- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Phreesia Inc(PHR)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PHR
11/13/2026: PHR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Phreesia Inc is a healthcare technology company providing a software platform that automates administrative tasks like patient registration and payments. The company is known for its strong position in the digital front door space and its ability to integrate with major electronic health record systems. Its primary growth opportunity lies in expanding its platform across more medical specialties and scaling its high-margin Life Sciences advertising network. Key risks include intense competition from integrated EHR vendors, potential macroeconomic pressures on physician budgets, and the need to achieve sustainable profitability. The stock is best suited for growth-oriented investors who can tolerate volatility while monitoring progress toward financial targets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Phreesia offers high revenue growth potential by digitizing the fragmented ambulatory healthcare market. |
| Momentum investor | Mixed fit | The stock often reacts significantly to revenue growth beats or misses, requiring a positive momentum signal to justify entry. |
| Value investor | Weak fit | The company is not yet consistently profitable, making traditional value metrics like P/E ratios inapplicable. |
| Dividend investor | Weak fit | Phreesia does not pay dividends and prioritizes capital reinvestment. |
| Low-risk investor | Weak fit | High growth, non-profitable SaaS companies typically experience higher volatility than established, cash-flow-positive firms. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | As a growth stock, Phreesia's price can fluctuate significantly based on interest rates and quarterly performance. |
| Valuation risk | Medium / high | High price-to-sales ratios create sensitivity to any slowdown in growth expectations. |
| Competition risk (EHR integration) | Medium / high | Large EHR vendors like Oracle may continue to bundle competing features into their existing platforms. |
| Business quality | Medium | While the platform has sticky attributes, the company must prove long-term sustainable profitability. |
| Dividend income | Low / none | Income-focused investors will not find suitability here as no payouts are offered. |
| Execution risk | Medium | Scaling sales and onboarding in a fragmented healthcare market requires consistent, effective execution. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 787.68M USD | Price to earnings Ratio 74.65 | 1Y Target Price 13.87 |
Price to earnings Ratio 74.65 | 1Y Target Price 13.87 | ||
Volume (30-day avg) 645.7K shares | Beta 0.72 | 52 Weeks Range 7.77 - 21.77 | Updated Date 11/14/2026 |
52 Weeks Range 7.77 - 21.77 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.17 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Health Information Services
- BUY participation
- 100.0%
- Active BUY / eligible
- 4 / 4
- 30-Day BUY Count Change
- +2
Eligible universe: 4 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 10.92% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Phreesia Platform | Subscription and transaction-based fees from healthcare providers for patient intake software. | This is the core SaaS engine of the company, providing recurring, predictable revenue. |
| Life Sciences | Revenue from pharmaceutical companies for targeted patient education and advertising. | This is a high-margin, network-based segment that leverages patient data to drive growth. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE 74.65 | Forward PE 14.18 | Enterprise Value 778.34M | Price to Sales(TTM) 1.55 |
Enterprise Value 778.34M | Price to Sales(TTM) 1.55 | ||
Enterprise Value to Revenue 1.53 | Enterprise Value to EBITDA 15.56 | Shares Outstanding 62.07M | Shares Floating 49.23M |
Shares Outstanding 62.07M | Shares Floating 49.23M | ||
Percent Insiders 6.35 | Percent Institutions 95.72 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

